Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 288


Clinical inertia in the treatment of hyperglycemia in type 2 diabetes patients in primary care.

Mata-Cases M, Benito-Badorrey B, Roura-Olmeda P, Franch-Nadal J, Pepió-Vilaubí JM, Saez M, Coll-de-Tuero G; GEDAPS (Primary Care Group for the study of Diabetes) of the Catalonian Society of Family and Community Medicine.

Curr Med Res Opin. 2013 Nov;29(11):1495-502. doi: 10.1185/03007995.2013.833089. Epub 2013 Sep 6.


Clinical inertia in patients with T2DM requiring insulin in family practice.

Harris SB, Kapor J, Lank CN, Willan AR, Houston T.

Can Fam Physician. 2010 Dec;56(12):e418-24.


[INERTIA study: Clinical inertia in non-insulinized patients on oral hypoglycemic treatment. A study in Spanish primary and specialty care settings].

González-Clemente JM, Font B, Lahoz R, Llauradó G, Gambús G; Grupo de investigadores del Estudio INERCIA.

Med Clin (Barc). 2014 Jun 6;142(11):478-84. doi: 10.1016/j.medcli.2013.02.032. Epub 2013 Apr 23. Spanish.


Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.

Levin PA, Wei W, Zhou S, Xie L, Baser O.

J Manag Care Spec Pharm. 2014 May;20(5):501-12.


Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study.

Raebel MA, Ellis JL, Schroeder EB, Xu S, O'Connor PJ, Segal JB, Butler MG, Schmittdiel JA, Kirchner HL, Goodrich GK, Lawrence JM, Nichols GA, Newton KM, Pathak RD, Steiner JF.

Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):699-710. doi: 10.1002/pds.3610. Epub 2014 Mar 18.


Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).

Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, Levin SR, Sawin CT, Silbert CK.

Diabetes Care. 1998 Apr;21(4):574-9.


Diabetes in urban African-Americans. XVI. Overcoming clinical inertia improves glycemic control in patients with type 2 diabetes.

Cook CB, Ziemer DC, El-Kebbi IM, Gallina DL, Dunbar VG, Ernst KL, Phillips LS.

Diabetes Care. 1999 Sep;22(9):1494-500.


Association of antidiabetic therapies to glycemic control and to body weight in type 2 diabetes: a German multicenter analysis on 9294 patients.

Schütt M, Kern W, Zimmermann A, Busch P, Kerner W, Voll A, Wagner C, Kann PH, Dapp A, Holl RW; DPV initiative; German BMBF Competence Network Diabetes mellitus.

Exp Clin Endocrinol Diabetes. 2010 Aug;118(8):490-5. doi: 10.1055/s-0030-1249024. Epub 2010 Mar 3.


Glycemic control and use of A1c in primary care patients with type 2 diabetes mellitus.

Alonso-Fernández M, Mancera-Romero J, Mediavilla-Bravo JJ, Comas-Samper JM, López-Simarro F, Pérez-Unanua MP, Iturralde-Iriso J; Work Group of Diabetes SEMERGEN (Sociedad Española de Médicos de Atención Primaria).

Prim Care Diabetes. 2015 Oct;9(5):385-91. doi: 10.1016/j.pcd.2015.01.006. Epub 2015 Feb 14.


Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.

Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS.

Diabetes Care. 1995 Aug;18(8):1113-23.


Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.

Khunti K, Nikolajsen A, Thorsted BL, Andersen M, Davies MJ, Paul SK.

Diabetes Obes Metab. 2016 Apr;18(4):401-9. doi: 10.1111/dom.12626. Epub 2016 Feb 9.


Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in Asian patients with diabetes: The Registry for Assessing OAD Usage in Diabetes Management (REASON) Asia study.

Vichayanrat A, Matawaran BJ, Wibudi A, Ferdous HS, Aamir AH, Aggarwal SK, Bajpai S.

J Diabetes. 2013 Sep;5(3):309-18. doi: 10.1111/1753-0407.12038. Epub 2013 May 28.


Medical care of type 2 diabetes mellitus in light of international and national recommendations: a retrospective analysis.

Burgmann K, Fatio S, Jordi B, Rutishauser J.

Swiss Med Wkly. 2013 Oct 25;143:w13871. doi: 10.4414/smw.2013.13871.


Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents.

Vinik AI, Cincotta AH, Scranton RE, Bohannon N, Ezrokhi M, Gaziano JM.

Endocr Pract. 2012 Nov-Dec;18(6):931-43. doi: 10.4158/EP12187.OR. Erratum in: Endocr Pract. 2013 Jan-Feb;19(1):179.


Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.

Rajpathak SN, Rajgopalan S, Engel SS.

J Diabetes Complications. 2014 Nov-Dec;28(6):831-5. doi: 10.1016/j.jdiacomp.2014.06.004. Epub 2014 Jun 19.


Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables.

Ji LN, Lu JM, Guo XH, Yang WY, Weng JP, Jia WP, Zou DJ, Zhou ZG, Yu DM, Liu J, Shan ZY, Yang YZ, Hu RM, Zhu DL, Yang LY, Chen L, Zhao ZG, Li QF, Tian HM, Ji QH, Liu J, Ge JP, Shi LX, Xu YC.

BMC Public Health. 2013 Jun 21;13:602. doi: 10.1186/1471-2458-13-602.


Characteristics of poorly controlled Type 2 diabetes patients in Swiss primary care.

Frei A, Herzog S, Woitzek K, Held U, Senn O, Rosemann T, Chmiel C.

Cardiovasc Diabetol. 2012 Jun 15;11:70. doi: 10.1186/1475-2840-11-70.


[Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: the INSTIGATE study].

Costi M, Smith H, Reviriego J, Castell C, Goday A, Dilla T.

Endocrinol Nutr. 2011 Jun-Jul;58(6):274-82. doi: 10.1016/j.endonu.2011.03.004. Spanish.


Supplemental Content

Support Center